Management of Persistent Major Depressive Disorder Without Remission

Initial Reassessment of Treatment Resistance

Conduct a comprehensive reassessment to uncover modifiable contributors (medication adherence, dosing adequacy, psychiatric and medical comorbidities, psychosocial stressors, and substance use) before altering therapy 1.
Poor medication adherence is a leading cause of apparent resistance and should be systematically evaluated 1.
Verify that each antidepressant trial has reached therapeutic dose and lasted at least 6–8 weeks before deeming it ineffective 1.
Screen for co‑occurring psychiatric disorders (e.g., anxiety, substance‑use, personality disorders, PTSD) that can sustain depressive symptoms 1.
Assess medical conditions that may mimic or worsen depression (e.g., thyroid dysfunction, chronic pain, sleep disorders) 1.
Identify ongoing psychosocial stressors such as abuse, relationship conflict, financial hardship, or occupational problems 1.
Evaluate alcohol and illicit‑drug use, which can blunt antidepressant response 2.

The American College of Physicians advises modifying treatment when an adequate response is not observed within 6–8 weeks of initiation 1.
Switching antidepressants: Change to a different second‑generation agent from another class (e.g., SSRI → SNRI or bupropion) when the current drug fails 1.
No single second‑generation antidepressant has proven superior as a second‑line option; selection should be guided by side‑effect profile, prior response, and targeted symptoms 1.
SNRIs may provide modestly greater efficacy than SSRIs but are associated with higher rates of nausea and vomiting 4.
Bupropion is linked to lower incidence of sexual dysfunction compared with SSRIs 3.

Adding cognitive‑behavioral therapy (CBT) to ongoing antidepressant medication markedly improves remission rates (≈ 57.5–78.7 % vs 31.0–45.2 % with medication alone) 6.
For patients who have not previously received psychotherapy, initiating CBT alongside a second‑generation antidepressant can nearly double remission rates in treatment‑resistant populations 7.
Evidence supporting specific pharmacologic augmentation agents in persistent depression remains limited 1.

Maintenance therapy should be continued for extended periods (years to lifelong) in individuals with multiple depressive episodes 8.
After achieving a satisfactory response, continue the antidepressant for at least 4–9 months to consolidate gains 8.
Patients with two or more episodes derive benefit from longer, potentially indefinite, maintenance treatment 8.
Conduct monthly monitoring for 6–12 months following symptom resolution, and consider extending surveillance up to 2 years in recurrent depression due to high relapse risk 9.

Re‑evaluate the patient’s status within 1–2 weeks of any treatment modification 10.
Use standardized rating scales (e.g., PHQ‑9, HAM‑D) to track depressive symptom severity 7.
Perform suicide‑risk assessment at every visit 10.
Monitor adverse effects with dedicated side‑effect scales 9.
Check treatment adherence regularly 9.
Review new or ongoing environmental stressors at each encounter 9.

Declaring treatment failure before a full 6–8‑week therapeutic trial at an adequate dose 1.
Reserving CBT as a last‑resort intervention rather than integrating it early in the care plan 7.
Adding further pharmacologic agents without first addressing treatable comorbidities, substance use, or psychosocial stressors 1.
Premature discontinuation of an effective antidepressant—maintain therapy for 4–9 months after response and consider years of maintenance for recurrent illness 8.
Inadequate monitoring, which can miss emerging suicidality or treatment failure 10.